AI assistant
MYRIAD GENETICS INC — Director's Dealing 2024
Sep 4, 2024
32566_dirs_2024-09-04_7ec6a89c-6362-4179-9851-24b67d12f072.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2024-09-03
Reporting Person: Reitan Colleen F (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-03 | Common Stock | S | 46012 | $27.946 | Disposed | 42533 | Direct |
Footnotes
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.45 to $28.47, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.